Catalog No.
AHK16201
Biological activity
Measured by its binding ability in a functional ELISA. When recombinant human CD112R/PVRIG (Cat #: AHK16201) is immobilized at 1 μg/mL, 100 μL/well, the concentration of recombinant human Nectin-2/CD112 that produces 50% of the optimal binding response is 0.4-2.4 μg/mL.
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Thr41-Leu172
Nature
Recombinant
Endotoxin level
<0.1 EU/μg of the protein by the LAL method.
Purity
>90% as determined by SDS-PAGE.
Accession
Q6DKI7
Applications
Bioactivity, ELISA, Immunogen, SDS-PAGE, WB
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
C7orf15, CD112R, CD112 receptor, Poliovirus receptor-related immunoglobulin domain-containing protein, PVRIG, Transmembrane protein PVRIG
Structure-guided engineering of CD112 receptor variants for optimized immunotherapy., PMID:40285356
Peripheral-central network analysis of cancer cachexia status accompanied by the polarization of hypothalamic microglia with low expression of inhibitory immune checkpoint receptors., PMID:38685046
PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways., PMID:38588410
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT., PMID:37675979
Nonredundant Upregulation of CD112R (PVRIG) and PD-1 on Cytotoxic T Lymphocytes Located in T Cell Nests of Colorectal Cancer., PMID:36788088
Emergence of the CD226 Axis in Cancer Immunotherapy., PMID:35812451
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy., PMID:34507594
Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy., PMID:34433460
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors., PMID:34174928
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy., PMID:33298247
Targeting novel inhibitory receptors in cancer immunotherapy., PMID:33288379
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer., PMID:30132062
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions., PMID:28623459
Identification of CD112R as a novel checkpoint for human T cells., PMID:26755705
For research use only. Not for human or drug use.
